Latest news with #SOUTH
Irish Examiner
4 days ago
- Entertainment
- Irish Examiner
Siya Kolisi: Let's get over cramp controversy. It's rugby, it's entertainment
SOUTH Africancaptain Siya Kolisi has backed his compatriot Jaden Hendrikse over the cramp controversy which stirred a hornet's noest in the wake of Munster's URC quarter final defeat to the Sharks last Saturday in Durban. The home side won 6-4 after the game ended in a 24-24 draw but Sharks scrum-half Hendrikse has been criticised for unsportsmanlike behaviour after going down with cramps and while on the ground, winking at Munster ten Jack Crowley as he was getting ready to take his second sudden death penalty. Springbok coach Rassie Erasmus has already weighed in, as did Leinster assistant coach Jacques Nienaber who made light of the controversy. 'We stand with Jaden,' Kolisi, the Sharks' No. 8 said. 'Jaden is competitive. There has been banter everywhere in the game. We've seen it from players from all over the world. It's normal. These things happen. 'And people can say what they like. It's banter between two players, and that's all it is. And that's what Jaden is. From our side, he knows we're backing him all the way. You can see he was definitely cramping,' Kolisi said. 'I get people saying stuff to me in the game. I don't moan about it. We just carry on, or you react however you want to react. It is what it is. We are supporting him, we stand with Jaden. 'You've seen the ones that happened during the World Cup. And some guys who were on the field there have also done it to other people. 'Let's get over it, it's rugby, it's entertainment. That's what people want. They are going to go see the next game because they think things like this happen. Guys want to celebrate. Let people be themselves. 'We've all got our own ways of dealing with stuff on the field. Come on, we can't box each other in, and we can't all be the same, we are not robots, we are human beings. 'We express how we want to express, sometimes you are going to take it, and sometimes you are going to give it."
Yahoo
13-02-2025
- Business
- Yahoo
Cytokinetics to Announce Fourth Quarter Results on February 27, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cytokinetics Q4 2024 Earnings Conference Call. Upon registration, participants will receive a dial-in number and a unique passcode to access the call. An archived replay of the webcast will be available via Cytokinetics' website for six months. About Cytokinetics Cytokinetics is a late-stage, muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a potential next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit and follow us on X, LinkedIn, Facebook and YouTube. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the 'Act'). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics' product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlines in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact:Cytokinetics Diane WeiserSenior Vice President, Corporate Affairs(415) 290-7757
